[1]刘伟信*,曾琴,徐红.卵巢过度刺激综合征防治研究进展[J].中国计划生育和妇产科,2017,(1):20- 23,28.
点击复制

卵巢过度刺激综合征防治研究进展
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2017年1期
页码:
20- 23,28
栏目:
综述
出版日期:
2017-01-25

文章信息/Info

作者:
刘伟信1*;  曾琴1;  徐红2
1. 610045四川成都，四川省妇幼保健院/四川省妇女儿童医院生殖医学重点实验室；2.610075四川成都,成都中医药大学第二临床医学院
关键词:
卵巢过度刺激综合征; 发病机制; 高危因素; 预测指标; 预防; 治疗
摘要:
卵巢过度刺激综合征是辅助生殖技术主要并发症之一，严重危害患者身体健康，探讨卵巢过度刺激综合征的发病机制、高危因素、预测指标、预防和治疗策略，对临床中有效预防和治疗多囊卵巢综合征具有重要意义。

参考文献/References:

［1］Meldrum R. Preventing severe OHSS has many different facets ［J］. Fertil Steril, 2012, 97(3): 536-538. ［2］Wang Hao, Horng Gwo, Chang Lin, et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor ［J］. J Clin Endocrinol Metab, 2002, 87(7): 3300-3308. ［3］Ocal Pelin, Sahmay Sezai, Cetin Meral, et al. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles ［J］. J Assist Reprod Genet, 2011, 28(12): 1197-1203. ［4］Aboulghar A, Mansour T. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures ［J］. Hum Reprod Update, 2003, 9(3): 275-289. ［5］Kasum Miro. New insights in mechanisms for development of ovarian hyperstimulation syndrome ［J］. Coll Antropol, 2010, 34(3): 1139-1143. ［6］Gnoth C, Schuring AN, Friol K, et al. Relevance of anti-Mullerian hormone measurement in a routine IVF program［J］. Hum Reprod, 2008, 23(6): 1359-1365. ［7］Lyons A, Wheeler A, Frishman N, et al. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors ［J］. Hum Reprod, 1994, 9(5): 792-799. ［8］Lee TH, Liu CH, Huang CC, et al. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles［J］. Hum Reprod, 2008, 23(1): 160-167. ［9］Nakhuda S, CHU Micheline, Wang G, et al. Elevated serum müllerian-inhibiting substance May be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization ［J］. Fertil Steril, 2006, 85(5): 1541-1543. ［10］Kwee J, Elting ME, Schats R, et al. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization［J］. Reprod Biol Endocrinol, 2007, 5(1): 9. ［11］Aflatoonian Abbas, Oskouian Homa, Ahmadi Shahnaz, et al. Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2-6 mm) ［J］. J Assist Reprod Genet, 2009, 26(6): 319-325. ［12］Papanikolaou G, Pozzobon Cristina, Kolibianakis M, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles［J］. Fertil Steril, 2006, 85(1): 112-120. ［13］陈颖，郁琦，张以文，等血清抑制素 B在体外受精-胚胎移植超排卵周期中预测卵巢反应性的预测价值［J］中华妇产科杂志，2006，41（6）：368-371 ［14］Kahnberg Annika, Enskog Anders, Brnnstrm Mats, et al. Prediction of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization［J］. Acta Obstet Gynecol Scand, 2009, 88(12): 1373-1381. ［15］Steward G, Lan Lan, Shah A, et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles［J］. Fertil Steril, 2014, 101(4): 967-973. ［16］Sousa M, Cunha M, Teixeira Da Silva J, et al. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles［J］. Reprod Biol Endocrinol, 2015, 13(1): 1-9. ［17］Christin-Maitre S, Hugues JN, Recombinant FSH Study Grp. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome［J］. Human Reproduction, 2003, 18(8): 1626-1631. ［18］Borges Edson, Braga Paes, Setti S, et al. Strategies for the management of OHSS: Results from freezing-all cycles［J］. JBRA assisted reproduction, 2016, 20(1): 8-12. ［19］Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology［J］.Cochrane Database Syst Rev, 2011(5): CD001750. ［20］Doody KJ, Schnell VL, Foulk RA, et al. Endometrin for luteal phase support in a randomized,controlled,openlabel,prospective in-vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation ［J］. Fertil Steril, 2009, 91(4): 1012-1017. ［21］Várnagy Akos, Bódis József, Mánfai Zoltán, et al. Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome ［J］. Fertil Steril, 2010, 93(7): 2281-2284. ［22］Huang Xiaman, Wang Pin, Tal Reshef, et al. A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures［J］. Int J Gynaecol Obstet, 2015, 131(2): 111-116. ［23］王爱华，刘小艳，刘祺，等静脉钙剂预防卵巢过度刺激综合征有效性和安全性的Meta分析［J］中国循证医学杂志，2016，16（8）：920-925 ［24］Chen Hua, LV Jie, WU Xin, et al. Blastocyst-stage versus cleavage-stage embryo transfer in the first frozen cycles of OHSS-risk patients who deferred from fresh embryo transfer［J］. Gynecol Endocrinol, 2015, 31(9): 698-701. ［25］Suikkari Maria. In-vitro maturation: its role in fertility treatment［J］. Curr Opin Obstet Gynecol, 2008, 20(3): 242-248. ［26］Nardo G, Cheema Priya, Gelbaya A, et al. The optimal length of “coasting protocol” in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization［J］. Hum Fertil (Camb), 2006, 9(3): 175-180. ［27］Fiedler K ED, preventing ovarian hyperstimulation syndrome. (OHSS):the need for individualized not standardized treatment［J］. Reprod Biol Endocrinol, 2012, 10(1): 1-10. ［28］Venetis A, Kolibianakis M, Toulis A, et al. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis ［J］. Fertil Steril, 2011, 95(1): 188-196, 196.e1-3. ［29］Rova Karin, Passmark Henrik, Lindqvist G. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles ［J］. Fertil Steril, 2012, 97(1): 95-100.

相似文献/References:

[1]袁媛,周灿权.控制性超排卵中卵巢高反应与辅助生殖的安全运行[J].中国计划生育和妇产科,2013,(01):0.
　YUAN Yuan,ZHOU Can-quan Reproductive Research Center,The First Affiliated Hospital of Sun Yat-sen University,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(1):0.
[2]何茜冬,唐妍,郑妍,等.诱发排卵治疗中血清白细胞介素-6对卵巢过度刺激综合征的预测作用[J].中国计划生育和妇产科,2014,(05):0.
　HE Qian-dong,TANG-Yan,ZHENG-Yan,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2014,(1):0.
[3]张云鹤,李广太*,刘珊珊.子宫静脉内平滑肌瘤1例及文献复习[J].中国计划生育和妇产科,2017,(2):20.
[4]洪玮,段华*,汪沙.脑源性神经营养因子与受体在子宫内膜异位症 发生发展及相关症状中作用的研究进展[J].中国计划生育和妇产科,2017,(3):27.
[5]洪莎莎 综述,洪莉* 审校.盆腔器官脱垂研究进展[J].中国计划生育和妇产科,2017,(9):19.
[6]李霞,孔为民*,姜艳.妊娠期血小板减少疾病研究进展[J].中国计划生育和妇产科,2017,(11):19.
[7]焦婷婷,李建华,郝翊,等.促性腺激素释放激素拮抗剂联合来曲唑治疗卵巢过度刺激综合征的临床分析[J].中国计划生育和妇产科,2017,(11):34.
　JIAO Ting-ting,LI Jian-hua,HAO Yi,et al.Clinical analysis of GnRH-a combined with letrozole in the treatment of ovarian hyperstimulation syndrome[J].Chinese Journal of Family Planning & Gynecotokology,2017,(1):34.
[8]范云龙,杨建华.微生物在卵巢癌发病机制与治疗中的作用[J].中国计划生育和妇产科,2018,(5):24.
[9]宋晓磊,谢梅青*.子宫静脉内平滑肌瘤病的诊治进展[J].中国计划生育和妇产科,2018,(10):18.
[10]毛书霞,李宏波*,吴意赟,等.三维超声定量指标对体外受精-胚胎移植中发生卵巢过度刺激综合征的预测价值[J].中国计划生育和妇产科,2019,(2):41.
　MAO Shu-xia,LI Hong-bo*,WU Yi-yun,et al.Value of three-dimensional ultrasound in predicting ovarian hyperstimulation syndrome in IVF-ET[J].Chinese Journal of Family Planning & Gynecotokology,2019,(1):41.

更新日期/Last Update: 2017-01-25